## OIPE CIOS

## **AMENDMENTS**

## IN THE CLAIMS:

Under 37 C.F.R. § 1.121(c), please amend claims 17-20 as follows:

1-10. (canceled)

11. (previously presented) A phosphoramidate compound formed from an hydroxy functional or amino functional drug having the formula Drug-ZH, said compound having the formula:

 $R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$ 

wherein:

R is  $C_1$ - $C_4$  alkyl or - $(CH_2)_nX$ ;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom; and

the group R<sub>r</sub>CH<sub>2</sub>- is a biologically labile ester forming group.

- 12. (previously amended) The compound of claim 11 wherein the drug is an amino acid, a biologically active peptide, or a peptidomimetic.
- 13. (previously amended) The compound of claim 12 wherein Drug-ZH is a peptidomimetic having the formula:

$$\mathsf{HZ} - (\mathsf{CH_2})_{\mathsf{q}} [\mathsf{CHB}]_{\mathsf{k}} \mathsf{C}(\mathsf{O}) \mathsf{NHCH}(\mathsf{CH_3}) - \mathsf{O}$$

wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino, or C<sub>1</sub>-C<sub>4</sub> alkanoylamino.

14. (previously amended) The compound of claim 11 wherein the drug is a biologically active nucleotide analog.

15-16. (canceled)

17. (currently amended) A pharmaceutical-composition comprising a phosphoramidate compound formed from an hydroxy functional or amino functional drug compound having the formula Drug-ZH, said compound having the formula:

 $R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$ 

wherein

R is  $C_1$ - $C_4$  alkyl or - $(CH_2)_nX$ ;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom; and

the group R<sub>r</sub>CH<sub>2</sub>- is a biologically labile ester forming group; and a pharmaceutically acceptable carrier therefor.

- 18. (currently amended) The pharmaceutical composition of claim 17 wherein Drug-ZH is an amino acid, a biologically active peptide, or a peptidomimetic.
- 19. (currently amended) The pharmaceutical composition of claim 18 wherein Drug-ZH is a peptidomimetic having the formula:

$$HZ$$
  $(CH_2)_q[CHB]_kC(O)NHCH(CH_3)$   $O$ 

wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino, or C<sub>1</sub>-C<sub>4</sub> alkanoylamino.

- 20. (currently amended) The <del>pharmaceutical</del> composition of claim 17 wherein Drug-ZH is a nucleotide analog.
- 21. (previously presented) The compound of claim 11 wherein R is methyl; n is 4; X is chloro; the group R<sub>r</sub>CH<sub>2</sub>- is a radical having the formula:

$$H_2C$$
  $O$  ; and

Drug-ZH is a nucleotide analog having the formula:

wherein Z is oxygen.